Discussion To our knowledge, only 1 case of multiple myeloma presenting with fever and cholestasis has been previously reported. 1 Overall, few cases of fevers of unknown origin and myeloma have been ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the ...

Dr. Lentzsch is an internationally recognized expert in multiple myeloma and AL Amyloidosis; Co-Chairs the National Cancer Institute Myeloma Steering Committee; is an Associate Editor of Journal ...

Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff ...

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

Background: Amyloidosis, particularly light-chain (AL) amyloidosis, is a rare but serious complication of multiple myeloma (MM) that can significantly impact cardiac function, particularly among ...